Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 23 July 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Sphincterotomy vs sham does not reduce pain-related disability after cholecystectomy

A team of doctors examine the effect of endoscopic sphincterotomy for suspected sphincter of Oddi dysfunction on pain-related disability following cholecystectomy, reports this weeks issue of the Journal of the American Medical Association.

News image

Abdominal pain after cholecystectomy is common and may be attributed to sphincter of Oddi dysfunction.

Management often involves endoscopic retrograde cholangiopancreatography (ERCP) with manometry and sphincterotomy.

Professor Peter Cotton and colleagues from South Carolina, USA determined whether endoscopic sphincterotomy reduces pain, and whether sphincter manometric pressure is predictive of pain relief.

The team performed a multicenter, sham-controlled, randomized trial involving 214 patients with pain after cholecystectomy without significant abnormalities on imaging or laboratory studies, and no prior sphincter treatment or pancreatitis.

The patients were randomly assigned to undergo sphincterotomy or sham therapy at 7 referral medical centers, with a 1-year follow-up up to 2013.

After ERCP, patients were randomized to sphincterotomy or sham irrespective of manometry findings.
23% in the sphincterotomy group experienced successful treatment
Journal of the American Medical Association

Those randomized to sphincterotomy with elevated pancreatic sphincter pressures were randomized again to biliary or to both biliary and pancreatic sphincterotomies.

The team reported that 72 were entered into an observational study with conventional ERCP managemeny.

The researchers defined success of treatment as less than 6 days of disability due to pain in the prior 90 days both at months 9 and 12 after randomization, with no narcotic use and no further sphincter intervention.

The team found that 37% of patients in the sham treatment group vs 23% in the sphincterotomy group experienced successful treatment.

Of the patients with pancreatic sphincter hypertension, 30% who underwent dual sphincterotomy, and 20% who underwent biliary sphincterotomy alone experienced successful treatment.

The research team observed that 26% of patients treated, and 34% of patients in the sham group underwent repeat ERCP interventions.

Manometry results were not associated with the outcome.

The team noted that no clinical subgroups appeared to benefit from sphincterotomy more than others.

Pancreatitis occurred in 11% of patients after primary sphincterotomies, and in 15% in the sham group.

Of the nonrandomized patients in the observational study group, 24% who underwent biliary sphincterotomy, 31% who underwent dual sphincterotomy, and 17% who did not undergo sphincterotomy had successful treatment.

Professor Cotton's team concludes, "In patients with abdominal pain after cholecystectomy undergoing ERCP with manometry, sphincterotomy vs sham did not reduce disability due to pain."

"These findings do not support ERCP and sphincterotomy for these patients."

JAMA 2014;311(20):2101-2109
29 May 2014

Go to top of page Email this page Email this page to a colleague

 22 July 2016 
Fecal calprotectin and IBD
 22 July 2016 
Duodenal villous atrophy and celiac disease
 22 July 2016 
Upper GI lesions at primary diagnosis in IBD
 21 July 2016 
Radiofrequency ablation in Barrett's
 21 July 2016 
HCV eradication and inflammation in cirrhotic patients
 21 July 2016 
Surveillance of Barrett's
 20 July 2016 
Nonselective β-blockers and survival in cirrhosis
 20 July 2016 
Adolescent body mass index and and colorectal cancer risk
 20 July 2016 
Genetic biomarkers and IBD treatment response
 19 July 2016 
Prevention of chemotherapy-induced nausea and vomiting
 19 July 2016 
Longterm clinical follow-up of living liver donors
 19 July 2016 
Screening diabetic patients for NAFLD
 18 July 2016 
Rectal neuroendocrine tumors
 18 July 2016 
Liver stiffness measurement in chronic liver disease
 18 July 2016 
Liver cancer prediction scores in Hep B
 15 July 2016 
Patient reported outcomes in celiac disease
 15 July 2016 
Tonsillectomy and IBD risk
 15 July 2016 
Trainee IBD education in the USA
 14 July 2016 
Screening for familial pancreatic cancer
 14 July 2016 
Fecal calprotection for IBD prognosis
 14 July 2016 
Perianal surgery risk in Crohn's
 13 July 2016 
Lung transplant outcomes in Hep C
 13 July 2016 
Psychological comorbidity and postinfectious IBS
 13 July 2016 
Graft selection strategy in living donor liver transplants
 12 July 2016 
Treatment of pediatric acute liver failure
 12 July 2016 
Therapy for iron deficiency anemia in IBD
 12 July 2016 
Surveillance endoscopy in Barrett's esophagus
 11 July 2016 
Disturbed sleep and IBS
 11 July 2016 
Transition to adulthood in celiac disease
 11 July 2016 
Factors that influence access to liver transplant
 08 July 2016 
Mortality and peptic ulcers
 08 July 2016 
Statins and cirrhosis in Hep B
 08 July 2016 
Genetic risk score and body mass index
 07 July 2016 
Predicting food triggers in eosinophilic esophagitis
 07 July 2016 
Extraperitoneal vs transperitoneal colostomy for hernia
 07 July 2016 
Predictors fecal transplant failure in C. diff infection
 06 July 2016 
Therapies for Hep B cure
 06 July 2016 
Hospital volume and liver cancer survival
 06 July 2016 
Adverse events after outpatient colonoscopy
 05 July 2016 
Colorectal surgery and dialysis
 05 July 2016 
Non-invasive scoring systems for fibrosis in NAFLD
 05 July 2016 
Exercise and gastroesophageal reflux
 04 July 2016 
Guidelines on PPI and NSAID prescription
 04 July 2016 
Rectal cancer surgery checklist
 04 July 2016 
Autoimmunity in eosinophilic esophagitis and families
 01 July 2016 
Outcome measures in celiac disease
 01 July 2016 
Growth factor activity and IBD
 01 July 2016 
Aspirin and colorectal cancer
 30 June 2016 
Staging system for familial adenomatous polyposis
 30 June 2016 
Antibiotics in children and obesity
 30 June 2016 
IBS-type symptoms in pediatric IBD
 29 June 2016 
Hep C eradication in people who inject drugs
 29 June 2016 
Anti-tumor necrosis factor in mothers and newborns
 29 June 2016 
Progression to esophageal carcinoma in Barrett's
 28 June 2016 
Gastric cancer screening in the USA
 28 June 2016 
Cancer recurrence after immune-suppressive therapies
 28 June 2016 
Acute severe ulcerative colitis
 27 June 2016 
Tobacco smoking and ulcerative colitis
 27 June 2016 
Epidemiology of NAFLD
 27 June 2016 
The Toronto Consensus for H. pylori treatment

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us